Literature DB >> 12036894

Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell.

Patricia A Taylor1, Thea M Friedman, Robert Korngold, Randolph J Noelle, Bruce R Blazar.   

Abstract

We previously reported that ex vivo blockade of the CD40:CD40L costimulatory pathway in primary mixed lymphocyte reaction cultures resulted in profound in vitro secondary hyporesponsiveness and 30-fold or greater protection from graft-versus-host-disease (GVHD) lethality. Present studies demonstrate that tolerance induction via costimulatory blockade also results in the generation of a potent immunoregulatory cell that inhibits both naive and primed alloresponses. The immunoregulatory capacity was dependent upon cell-to-cell contact that prevented the full activation of the naive or primed cells. The inhibitory effect of tolerized cells did not preclude the response of naive T cells to nominal protein antigen if antigen was present at high concentration. However, under suboptimal antigen concentration, nonspecific inhibition of responses occurred. The tolerized regulatory cell population maintained a polyclonal T-cell receptor V beta repertoire that was broader than in control primed cultures. These data, the first to demonstrate that tolerance induction via CD40:CD40L costimulatory blockade results in potent regulatory function, are relevant to bone-marrow and solid-organ transplantation. The generation of potent immunoregulatory capacity during tolerization via CD40:CD40L blockade provides a fail-safe mechanism to control alloreactive T cells that may have escaped tolerization. These potent regulatory cells may be clinically exploitable for the treatment and prevention of GVHD or autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12036894     DOI: 10.1182/blood.v99.12.4601

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

Review 1.  TGF-beta, T-cell tolerance and anti-CD3 therapy.

Authors:  Ramireddy Bommireddy; Thomas Doetschman
Journal:  Trends Mol Med       Date:  2004-01       Impact factor: 11.951

2.  T regulatory cell suppression of colitis: the role of TGF-beta.

Authors:  R Duchmann; M Zeitz
Journal:  Gut       Date:  2006-05       Impact factor: 23.059

Review 3.  Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity.

Authors:  Rebecca L Crepeau; Mandy L Ford
Journal:  Expert Opin Biol Ther       Date:  2017-05-30       Impact factor: 4.388

4.  Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation.

Authors:  Jeffrey K Davies; Lee M Nadler; Eva C Guinan
Journal:  Sci Transl Med       Date:  2009-10-07       Impact factor: 17.956

Review 5.  Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).

Authors:  Bruce R Blazar; William J Murphy
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

6.  IL-10/TGF-beta-treated dendritic cells, pulsed with insulin, specifically reduce the response to insulin of CD4+ effector/memory T cells from type 1 diabetic individuals.

Authors:  Honorio Torres-Aguilar; Carmen Sánchez-Torres; Luis J Jara; Miri Blank; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2010-06-11       Impact factor: 8.317

7.  CD154 blockade abrogates allospecific responses and enhances CD4(+) regulatory T-cells in mouse orthotopic lung transplant.

Authors:  J M Dodd-o; E A Lendermon; H L Miller; Q Zhong; E R John; W M Jungraithmayr; F R D'Alessio; J F McDyer
Journal:  Am J Transplant       Date:  2011-08-09       Impact factor: 8.086

8.  GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28- CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression.

Authors:  Weston P Miller; Swetha Srinivasan; Angela Panoskaltsis-Mortari; Karnail Singh; Sharon Sen; Kelly Hamby; Taylor Deane; Linda Stempora; Jonathan Beus; Alexa Turner; Caleb Wheeler; Daniel C Anderson; Prachi Sharma; Anapatricia Garcia; Elizabeth Strobert; Eric Elder; Ian Crocker; Timothy Crenshaw; M Cecilia T Penedo; Thea Ward; Mingqing Song; John Horan; Christian P Larsen; Bruce R Blazar; Leslie S Kean
Journal:  Blood       Date:  2010-09-10       Impact factor: 22.113

9.  Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.

Authors:  Stephan Mielke; Katayoun Rezvani; Bipin N Savani; Raquel Nunes; Agnes S M Yong; John Schindler; Roger Kurlander; Victor Ghetie; Elizabeth J Read; Scott R Solomon; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2007-05-03       Impact factor: 22.113

Review 10.  Mechanism of cellular rejection in transplantation.

Authors:  Elizabeth Ingulli
Journal:  Pediatr Nephrol       Date:  2010-01       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.